Cargando…

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET

SIMPLE SUMMARY: Medullary thyroid carcinoma (MTC) is a rare neoplasm supported by a strong genetic determinism. This review summarizes the genetic landscape of MTC at both germline and somatic levels to understand the molecular basis and the natural history of the tumour, mainly but not exclusively,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahakian, Nicolas, Castinetti, Frédéric, Romanet, Pauline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572078/ https://www.ncbi.nlm.nih.gov/pubmed/37835559 http://dx.doi.org/10.3390/cancers15194865

Ejemplares similares

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms
por: Ceolin, Lucieli, et al.
Publicado: (2011)

Allel RET+3 : T a medullary thyroid cancer
por: Pławski, A, et al.
Publicado: (2011)

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
por: Romei, Cristina, et al.
Publicado: (2018)

Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2015)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

RET mutations in a large indian family with medullary thyroid carcinoma
por: Mahesh, D. M., et al.
Publicado: (2014)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
por: Prazeres, Hugo, et al.
Publicado: (2011)

Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency
por: Milićević, Sara, et al.
Publicado: (2021)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”
por: Prazeres, Hugo, et al.
Publicado: (2016)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

Somatic Mutations in the RET Protooncogene in Japanese and Chinese Sporadic Medullary Thyroid Carcinomas
por: Shan, Liang, et al.
Publicado: (1998)

Effect of 3′UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma
por: Ceolin, Lucieli, et al.
Publicado: (2016)

Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
por: Mulè, Chiara, et al.
Publicado: (2021)

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
por: Robbins, Richard J., et al.
Publicado: (2020)

A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma
por: Mohammadi, Masoumeh, et al.
Publicado: (2017)

RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency
por: Ramone, Teresa, et al.
Publicado: (2020)

Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma
por: Kesby, Nicholas, et al.
Publicado: (2023)

Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
por: Aydoğan, Berna İmge, et al.
Publicado: (2016)

Novel Point Mutations and Allele Loss at the RET Locus in Sporadic Medullary Thyroid Carcinomas
por: Uchino, Shinya, et al.
Publicado: (1998)

Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma
por: Bim, Larissa V., et al.
Publicado: (2019)

Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Large‐scale Analysis of Mutations in RET Exon 16 in Sporadic Medullary Thyroid Carcinomas in Japan
por: Takano, Torn, et al.
Publicado: (2001)

Selective Antitumor Activity of Datelliptium toward Medullary Thyroid Carcinoma by Downregulating RET Transcriptional Activity
por: Alqahtani, Tariq, et al.
Publicado: (2021)

A Korean Family of Familial Medullary Thyroid Cancer with Cys618Ser RET Germline Mutation
por: Jung, Jinhyang, et al.
Publicado: (2010)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

A Case of Medullary Thyroid Carcinoma with de novo V804M RET Germline Mutation
por: Choi, Young Sik, et al.
Publicado: (2013)

Haplotype Frequency of G691S/S904S in the RET Proto-Onco-gene in Patients with Medullary Thyroid Carcinoma
por: SHEIKHOLESLAMI, Sara, et al.
Publicado: (2014)

RET gene mutations spectrum in patients with medullary thyroid carcinoma (MTC) from Great Poland region
por: Kaczmarek-Ryś, Marta, et al.
Publicado: (2015)

Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997–2013: a nationwide study
por: Mathiesen, Jes Sloth, et al.
Publicado: (2019)

Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2017)

CRISPR/Cas9 RET Gene Knockout in Medullary Thyroid Carcinoma Cell-lines: Optimization and Validation
por: Zarif-Yeganeh, Marjan, et al.
Publicado: (2022)

RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation
por: Yue, Chia-Herng, et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Current and Emerging Medical Therapies in Pituitary Tumors
por: Sahakian, Nicolas, et al.
Publicado: (2022)

SAT540 A Case of Simultaneous Medullary Thyroid Cancer (MTC) And Papillary Thyroid Cancer (PTC) In a Patient With Germline RET Mutation
por: Vaghasia, Nishit, et al.
Publicado: (2023)

Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma
por: Hedayati, Mehdi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_upmtj3n0ni1mkb8gedpji3fhg0